The development course_The development course_Kintor Pharmaceutical Limited

lilin

这是描述信息

这是描述信息



搜索

Search

ABOUT US

关于开拓



2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2010
2009

Kintor Pharma Announces Completion of Phase I Clinical Trial of GT20029 in the US
Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
GT20029 IND Was Accepted by NMPA
The GT1708F project has been approved for clinical trials in China
The Group has signed a technical agreement with Peking University to introduce its c-Myc inhibitor project
The Group has obtained Series C investment of approximately RMB288 million
GT0918 (Proxalutamide tablets) project has been awarded as the National Special Project for "Significant Novel Drugs Development" during the 13th Five-Year Plan period
The IND application of GT0918 (Proxalutamide tablets) for breast cancer indications has been submitted to and accepted by NMPA in China
The GT0918 (Proxalutamide tablets) project has obtained clinical trials permission for prostate cancer indications in China and the United States, and phase I clinical trials have been launched in China
The Group has obtained Series A investment of approximately RMB20 million
The IND application of the Group's first project, GT0918 (Proxalutamide tablets), has been submitted for prostate cancer indications
Suzhou Kintor has received angel investment from Legend Star and Oriza Holdings
The Group's first project, GT0918 (Proxalutamide tablets), has been awarded as the National Special Project for "Significant Novel Drugs Development" during the 12th Five-Year Plan period
Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor" or the "Group") has been formally registered in Suzhou

+ -



About Us

Company Introduction Management Team Development Course Awards and Honours

R&D

Product Pipeline R&D Platform

Investor Relations

Corporate Governance Listing Documents Announcements & Circulars Email Subscription Center Webcasts & Presentations Contact Information

Human Resources

Talent Concept Campus Recruitment Social Recruitment Training and Development Employees’ Life

News Center

Company News Media Reports

Contact Us

Find Us

这是描述信息

About Us

Company Introduction

Management Team

Development Course

Awards and Honours

Business

Product Pipeline

Business Development

Investor Relations

Corporate Governance

Listing Documents

Announcements & Circulars

Webcasts & Presentations

Investor Enquiries

Email Subscription Center

Human Resources

Campus Recruitment

Social Recruitment

Training and Development

Employees’Life

News Center

Contact Information

Contact Us

Find Us

扫码关注

这是描述信息

WeChat

Copyright: Kintor Pharmaceutical Limited retains all copyrights. 苏ICP备19028699号-2 Powered by 3 00.cn

Complaints and Suggestions Tel: +86 512 62639935 Email: public@kintor.com.cn